Hyaluronic Acid vs I-PRF With Microneedling in Enhancing Peri-implant Soft Tissue
Hyaluronic Acid Versus I-PRF Combined With Microneedling for Peri Implant Soft Tissue Enhancement: A Randomized Controlled Clinical Trial
1 other identifier
interventional
42
0 countries
N/A
Brief Summary
This study aims to compare the use of microneedling alone versus with hyaluronic acid or i-PRF in conjunction with microneedling in peri-implant mucosa in the esthetic zone to test the superior increase in gingival thickness.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2
Started Oct 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 2, 2026
CompletedFirst Posted
Study publicly available on registry
August 6, 2026
CompletedStudy Start
First participant enrolled
October 30, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2028
Study Completion
Last participant's last visit for all outcomes
May 30, 2028
August 6, 2026
August 1, 2026
1.3 years
August 2, 2026
August 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Peri-implant gingival thickness
6 months
Study Arms (3)
Microneedling
NO INTERVENTIONmicroneedling into the peri-implant soft tissue site
Microneedling with Hyaluronic Acid (HA)
EXPERIMENTALMicroneedling into the peri-implant soft tissue site in addition to the use of HA, repeated 3 times with 7 days gap in between.
Microneedling with injectable platelet rich fibrin (I-PRF)
EXPERIMENTALMicroneedling into the peri-implant soft tissue site, in addition to the use of I-PRF, repeated 3 times with 7 days gap in between.
Interventions
Hyaluronic acid (HA) is a genuine linear glycosaminoglycan that is present within the extracellular matrix of connective, epithelial, and neural tissues.
Injectable PRF (i-PRF) is a notable method in enhancing soft tissue phenotypes, relying on its injectable form that can be well delivered to targeted areas to ensure proper distribution of growth factors and cytokines.
Eligibility Criteria
You may qualify if:
- Patients with delayed implants placed in the maxillary esthetic region in correct positioning and angulation
- Patients with peri-implant gingival thickness ≤ 1 mm
- Patients with healthy gingiva and who can maintain good oral hygiene around implants
You may not qualify if:
- Marginal bone loss ≤ 2 mm
- Patients with peri-implantitis or periodontitis
- Patients with systemic conditions or diseases impairing healing or soft tissue metabolism
- Pregnant or lactating females
- Patients taking medications affecting the gingiva
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MSc Student
Study Record Dates
First Submitted
August 2, 2026
First Posted
August 6, 2026
Study Start (Estimated)
October 30, 2026
Primary Completion (Estimated)
February 28, 2028
Study Completion (Estimated)
May 30, 2028
Last Updated
August 6, 2026
Record last verified: 2026-08